Virax Biolabs Group Ltd (VRAX) saw an uptrend of 8.42% in the recent trading with $0.65 being its most recent. The current price level -82.15% lower than the highest price of $3.62 marked by the stock while trading over the past 52-weeks, whereas it is 24.22% higher than the lowest price of $0.52 the company dropped to over past 52-weeks. The latest news story on VRAX appeared in (Insider Monkey) under the title “Virax Biolabs (VRAX) Falls 18% on Lack of Leads”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Virax Biolabs Group Ltd Earnings – What Happened With VRAX
Coming around sales and income figures on VRAX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
VRAX – Virax Biolabs Group Ltd Stock Earnings Estimates
The perspective of Virax Biolabs Group Ltd (NASDAQ:VRAX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.33 for stock’s EPS in the current quarter.
Virax Biolabs Group Ltd – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 4.34 million. VRAX does have institutional investors; and they hold 6.06% of the stock.
As on 2024-06-30, VIRTU FINANCIAL LLC was the top most holder in Virax Biolabs Group Ltd (NASDAQ:VRAX) with an ownership of 28058.0 shares of the company or 1.3984 of the stake worth $33000.0. The filing also reveals HRT FINANCIAL LP as the second largest holder in the company with a control over 1.2795 of the outstanding shares. Its stake is worth $29000.0 for having 25672.0 shares in hand.
RENAISSANCE TECHNOLOGIES LLC also came holding a key position in the company during the recent quarter and it now holds 0.5483 of the outstanding shares. With this there are now 3.0 institutions which have possession in VRAX’s shares.
Key Metrics for VRAX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Virax Biolabs Group Ltd has a debt to equity ratio of 0.07.
